share_log

Franchise Global Health Inc. Completes Plan of Arrangement With Flora Growth Corp.

Franchise Global Health Inc. Completes Plan of Arrangement With Flora Growth Corp.

特許經營全球健康有限公司完成與植物成長公司的安排計劃
newsfile ·  2022/12/23 18:22

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2022) - Franchise Global Health Inc. (TSXV: FGH) ("Franchise Global" or the "Company"), a multi-national operator in the medical cannabis and pharmaceutical industry with principal operations in Germany, is pleased to announce that the Company and Flora Growth Corp. (NASDAQ: FLGC) ("Flora") have completed the previously announced acquisition of the Company by Flora by way of a plan of arrangement under Division 5 of Part 9 of the Business Corporations Act (British Columbia) (the "Plan of Arrangement", and the transactions contemplated thereby referred to as the "Arrangement"), effective at 12:01 a.m. (Vancouver time) on December 23, 2022.

温哥華,不列顛哥倫比亞省-(Newsfile Corp.-2022年12月23日)-特許經營全球健康公司(TSXV:FGH)(“特許經營全球“或”公司主要業務在德國的醫用大麻和製藥行業跨國運營商)很高興地宣佈,該公司和弗洛拉增長公司(納斯達克股票代碼:FLGC)(植物區系“)已完成弗洛拉先前宣佈的對本公司的收購,該收購是以根據第9部第5分部的安排計劃進行的《商業公司法》(不列顛哥倫比亞省)(計劃 佈置,以及由此設想的交易被稱為佈置“),自2022年12月23日凌晨12時01分(温哥華時間)起生效。

The Arrangement and Plan of Arrangement were approved at a special meeting of shareholders of the Company held on December 13, 2022 (the "Meeting") and by a final order of the Supreme Court of British Columbia made on December 16, 2022.

本安排及安排計劃已於2022年12月13日舉行的本公司股東特別大會上通過(“會議“)和不列顛哥倫比亞省最高法院於2022年12月16日作出的最終命令。

Pursuant to the Plan of Arrangement, the former holders of common shares of the Company (the "Franchise Shares") received, for each Franchise Share held, approximately 0.29102 of a Flora common share (the "Flora Shares"), based on the exchange ratio determined in accordance with the Plan of Arrangement. The Flora Shares trade on The Nasdaq Capital Market under the symbol "FLGC". In accordance with the Plan of Arrangement, all Flora Shares issued to former holders of Franchise Shares are subject to restrictions on transfer for a period of 90-days following the completion of the Arrangement.

根據安排計劃,本公司前普通股持有人(“特許經營股份)每持有一股特許經營權股份,可獲得約0.29102的弗洛拉普通股(FLORA共享“),基於按照《安排方案》確定的交換比例。弗洛拉股份在納斯達克資本市場交易,交易代碼為”FLGC“。根據《安排計劃》,所有向前特許經營股份持有人發行的弗洛拉股份在安排完成後90天內均受轉讓限制。

It is expected that the Franchise Shares will be delisted from the TSX Venture Exchange on or about December 28, 2022. The Company intends to submit an application to the applicable securities regulators to cease to be a reporting issuer and to terminate its public reporting obligations.

預計加盟股份將於2022年12月28日左右從多倫多證券交易所創業板退市。本公司擬向適用的證券監管機構提出申請,要求其停止作為報告發行人並終止其公開報告義務。

As contemplated in the Arrangement Agreement, immediately prior to and conditional upon completion of the Arrangement, the Company assigned certain non-material assets to a director and officer of the Company (who also assumed all obligations thereunder) and settled outstanding debts and liabilities owing to certain directors, officers and consultants (and obtained releases from them) in consideration of the issuance of an aggregate of 12,249,999 common shares and 2,750,001 restricted share units of the Company (resulting in a total of 149,563,674 Franchise Shares being exchanged for an aggregate of 43,525,951 Flora Shares being issued to the former holders of Franchise Shares pursuant to the Plan of Arrangement). The issuance of Franchise Shares to directors and officers in settlement of outstanding debt was exempt from the "formal valuation" and "minority approval" requirements per sections 5.5(b) and 5.7(1)(a), respectively, of Multilateral Instrument 61-101.

如安排協議所預期,緊接安排完成前及完成後,本公司將若干無形資產轉讓予一名董事及本公司高級職員(彼等亦承擔其項下所有責任),並清償欠若干董事、高級職員及顧問的未償還債務及負債(並獲彼等免除),代價是發行合共12,249,999股本公司普通股及2,750,001股限制性股份(導致根據安排計劃向前特許經營股份持有人發行合共43,525,951股弗羅拉股份)。根據多邊文書61-101第5.5(B)節和第5.7(1)(A)節的規定,向董事和高級管理人員發行特許經營股份以清償未償債務,可分別免除“正式估值”和“少數人批准”的要求。

Further information about the Arrangement is set forth in the materials prepared by the Company in respect of the Meeting, which were mailed to holders of Franchise Shares and filed under the Company's SEDAR profile on the System for Electronic Document Analysis and Retrieval (SEDAR) at . Former holders of Franchise Shares are required to submit their share certificates or direct registration system (DRS) advices evidencing Franchise Shares, as well as duly completed letters of transmittal (which were mailed to former holders of Franchise Shares in connection with the Meeting), to TSX Trust Company, as depositary under the Arrangement, and follow the instructions provided in such letter of transmittal, in order to obtain the Flora Shares issued pursuant to the Arrangement.

有關該項安排的進一步資料載於本公司就會議準備的資料,該等資料已郵寄予特許股份持有人,並根據本公司關於電子文件分析及檢索系統(SEDAR)的SEDAR簡介存檔於。特許經營股份的前持有人須將證明特許經營股份的股票或直接登記系統(DRS)通知,以及已填妥的(與會議有關而郵寄給前特許經營股份持有人的)轉讓書提交予安排下的託管人多倫多證券交易所信託公司,並按照該轉讓書中的指示行事,以獲取根據該安排發行的FLORA股份。

About Franchise Global Health Inc.

關於特許經營全球健康公司

Franchise Global Health Inc., through its subsidiaries, is a multi-national operator in the medical cannabis and pharmaceutical industries, with principal operations in Germany and with operations, assets, strategic partnerships and investments internationally. The Company's business objective is to develop a fully-integrated, leading European medical cannabis business, with the goal of providing high-quality pharmaceutical grade medical cannabis to distribution partners and, ultimately, to patients, at competitive prices. For more information, please visit or visit the Company's SEDAR profile at .

特許經營全球健康公司通過其子公司是醫用大麻和製藥行業的跨國運營商,主要業務在德國,在國際上有業務、資產、戰略夥伴關係和投資。該公司的業務目標是發展一個全面整合的領先的歐洲醫用大麻業務,目標是向分銷夥伴提供高質量的藥用級醫用大麻,並最終以具有競爭力的價格向患者提供。欲瞭解更多信息,請訪問或訪問公司的SEDAR簡介,網址為:。

About Flora Growth Corp.

關於弗洛拉增長公司

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit or follow @floragrowthcorp on social media for more information.

FLORA正在打造一個互聯的、以設計為主導的植物性健康和生活方式品牌集體,旨在一次一個社區地提供世界上最引人注目的客户體驗。作為最大的户外大麻種植設施之一的運營商,弗洛拉利用天然的、具有成本效益的種植實踐,為其商業、品牌和生命科學部門提供大麻衍生品。有關更多信息,請訪問或關注社交媒體上的@floragrowthcorp。

Cautionary Statement Concerning Forward-Looking Information

關於前瞻性信息的警示聲明

This press release contains "forward-looking information" as defined by Canadian securities laws. Forward-looking information reflect the Company's current expectations and projections about future events at the time, and thus involve uncertainty and risk. Forward-looking information is often, but not always identified by the use of words such as "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar expressions generally identify forward looking information, and include statements in this press release concerning the expected timing by which Franchise Global will be de-listed from the TSX-V and the intention to apply to have Franchise Global cease being a reporting issuer and terminate its public reporting obligations. The statements including forward-looking information in this press release reflect management of the Company's good faith beliefs, are made as of the date it was issued. Statements containing forward-looking information in this press release are not guarantees of future results and subject to various known and unknown risks and uncertainties that may cause actual results to differ materially from those indicated in statements containing forward-looking information, including those risks and uncertainties discussed or referred to in the management information circular of the Company mailed in connection with the Meeting and the Company's other disclosure documents filed with applicable securities regulatory authorities in Canada, which are available on the Company's SEDAR profile at . You should not place undue reliance on any forward-looking information contained herein, which are based only on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any forward-looking information contained herein to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law.

本新聞稿包含加拿大證券法定義的“前瞻性信息”。前瞻性信息反映了公司目前對當時未來事件的預期和預測,因此涉及不確定性和風險。前瞻性信息通常但不總是通過使用諸如“相信”、“期望”、“預期”、“將”、“可能”、“將”、“應該”、“可能”、“計劃”、“估計”、“打算”、“預測”、“潛在”、“繼續”等詞語來標識,並且這些詞語和其他類似表達的否定通常標識前瞻性信息,並在本新聞稿中包括關於特許經營全球公司將從多倫多證券交易所-V退市的預期時間以及申請使特許經營全球公司不再是報告發行人並終止其公開報告義務的聲明。本新聞稿中包含前瞻性信息的陳述反映了公司管理層的誠信信念,這些陳述是在公司發佈之日作出的。本新聞稿中含有前瞻性信息的陳述不是對未來結果的保證,受到各種已知和未知的風險和不確定性的影響,這些風險和不確定性可能會導致實際結果與含有前瞻性信息的陳述中所述的結果大不相同,包括公司在與會議有關的郵寄的管理信息通告中討論或提到的風險和不確定因素,以及公司提交給加拿大適用證券監管機構的其他披露文件,這些文件可在公司的SEDAR簡介中查閲。您不應過分依賴本文中包含的任何前瞻性信息。, 這些數據僅基於本公司目前可獲得的信息。除適用法律要求外,公司沒有義務公開更新或修改本文中包含的任何前瞻性信息,以反映本新聞稿發佈之日後基本假設或因素、新信息、數據或方法、未來事件或其他變化的變化。

For further information, please contact:

如需更多信息,請聯繫:

Franchise Global Health Inc.

特許經營全球健康公司。

Clifford Starke, CEO and Executive Chairman
Telephone: (778) 847-1880
Email: starke@franchiseglobalhealth.com

首席執行官兼執行主席克利福德·斯塔克
電話:(778)847-1880
電子郵件:starke@FracteriseglobalHealth.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.

多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論